{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T21:46:57Z","timestamp":1776030417939,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eli Lilly Japan K.K., Hyogo, Japan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study assessed the safety and effectiveness of selpercatinib, a selective rearranged during transfection (RET) kinase inhibitor, in patients with RET fusion-positive non-small cell lung cancer (NSCLC) in real-world clinical practice in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-arm, multicenter, prospective observational study included patients with RET fusion-positive NSCLC who received at least one dose of selpercatinib between February 2022 and October 2023. Data were extracted from medical records and entered into an electronic data capture (eDC) system. Safety (adverse events [AEs] and AEs of special interest [AESIs]) and effectiveness (tumor response, overall survival [OS]) were assessed over 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 243 patients (median age: 67\u00a0years; 56% females), AEs occurred in 86.0% of patients, with Grade\u00a0\u2265\u00a03 AEs in 48.1% and serious AEs (SAEs) in 24.7%. The most common AEs (\u226510%) included hypertension (23.5%), abnormal hepatic function (21.0%), rash (11.1%), aspartate aminotransferase increase (10.3%), and diarrhea (10.3%). AEs led to treatment modifications, including dose interruption (54.7%), dose reduction (14.8%), and discontinuation (6.2%). AESIs included liver injury (44.0%), hypertension-related events (23.9%), and hypersensitivity (MedDRA preferred term; 9.9%). The overall response rate was 58.8%, comprising complete response in 4.5% and partial response in 54.3% of patients. Median OS was not reached; the 12-month survival rate was 80.9% (95% CI, 74.9\u201385.6).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world data showed selpercatinib to be effective in patients with RET fusion-positive NSCLC in Japan, with a favorable safety profile and no new safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf220","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:35:18Z","timestamp":1767098118000},"page":"435-446","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effectiveness of selpercatinib in patients with\n                    <i>RET<\/i>\n                    fusion-positive non-small cell lung cancer in real-world clinical practice: a postmarketing study in Japan"],"prefix":"10.1093","volume":"56","author":[{"given":"Yucherng","family":"Chen","sequence":"first","affiliation":[{"name":"Safety Medical , Global Patient Safety & Solutions, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo, 651-0086,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Mori","sequence":"additional","affiliation":[{"name":"Global Statistical Science Japan , Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo, 651-0086,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Wakabayashi","sequence":"additional","affiliation":[{"name":"Japan Drug Development & Medical Affairs , Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo, 651-0086,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-9531","authenticated-orcid":false,"given":"Kevin Y","family":"Urayama","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology , Global Patient Safety & Solutions, Eli Lilly Japan K.K., 5-1-28, Isogamidori, Chuo-ku, Kobe, Hyogo, 651-0086,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"2026041217380815900_ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026041217380815900_ref2","volume-title":"Global cancer observatory: Cancer today","author":"Ferlay","year":"2024"},{"key":"2026041217380815900_ref3","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1111\/cas.15439","article-title":"Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: a post-marketing surveillance","volume":"113","author":"Yamamoto","year":"2022","journal-title":"Cancer Sci"},{"key":"2026041217380815900_ref4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041217380815900_ref5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat Med"},{"key":"2026041217380815900_ref6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041217380815900_ref7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041217380815900_ref8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/oncolo\/oyac264","article-title":"RET fusion-positive non-small cell lung cancer: the evolving treatment landscape","volume":"28","author":"Novello","year":"2023","journal-title":"Oncologist"},{"key":"2026041217380815900_ref9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41120-024-00094-z","article-title":"Recent progress of small-molecule of RET inhibitors against non-small cell lung cancer","volume":"10","author":"Shen","year":"2024","journal-title":"AAPS Open"},{"key":"2026041217380815900_ref10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041217380815900_ref11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"2026041217380815900_ref12","volume-title":"RETEVMO (selpercatinib) capsules","author":"Pharmaceuticals and Medical Devices Agency","year":"2024"},{"key":"2026041217380815900_ref13","volume-title":"RETEVMO (selpercatinib) capsules, for oral use; RETEVMO (selpercatinib) tablets, for oral use[EB\/OL]","author":"U.S. Food and Drug Administration","year":"2024"},{"key":"2026041217380815900_ref14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041217380815900_ref15","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041217380815900_ref16","first-page":"669","article-title":"Efficacy and safety analysis of selpercatinib in patients with RET fusion-positive non-small cell lung cancer-results from the Japanese subset of a global phase 1\/2 study","volume":"49","author":"Nishio","year":"2022","journal-title":"Gan To Kagaku Ryoho"},{"key":"2026041217380815900_ref17","volume-title":"Pharmaceuticals and medical devices agency (PMDA)","author":"Retevmo (selpercatinib) Risk Management Plan","year":"2024"},{"key":"2026041217380815900_ref18","first-page":"6","volume-title":"Reactions weekly","author":"FAERS data identify three unreported selpercatinib-related AEs","year":"2024"},{"key":"2026041217380815900_ref19","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1186\/s12885-024-13250-1","article-title":"Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database","volume":"24","author":"Qian","year":"2024","journal-title":"BMC Cancer"},{"key":"2026041217380815900_ref20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jtho.2022.02.004","article-title":"Hypersensitivity reactions to selpercatinib treatment with or without prior immune checkpoint inhibitor therapy in patients with NSCLC in LIBRETTO-001","volume":"17","author":"McCoach","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026041217380815900_ref21","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.xcrm.2023.101332","article-title":"Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers","volume":"4","author":"Nardo","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026041217380815900_ref22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jdcr.2024.06.008","article-title":"Unique hypersensitivity syndrome secondary to selpercatinib","volume":"50","author":"Srikakolapu","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2026041217380815900_ref23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026041217380815900_ref24","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3390\/cancers15061766","article-title":"Hepatotoxicity of small molecule protein kinase inhibitors for cancer","volume":"15","author":"Vigano","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026041217380815900_ref25","doi-asserted-by":"crossref","first-page":"102805","DOI":"10.1016\/j.ctrv.2024.102805","article-title":"Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: a critical review of the literature","volume":"129","author":"Desage","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026041217380815900_ref26","doi-asserted-by":"publisher","first-page":"e2200708","DOI":"10.1200\/PO.22.00708","article-title":"Intracranial activity of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer in the phase II LIBRETTO-321 trial. JCO precis","volume":"7","author":"Cheng","year":"2023","journal-title":"Oncologia"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/4\/435\/66569370\/hyaf220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/4\/435\/66569370\/hyaf220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T21:38:14Z","timestamp":1776029894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/4\/435\/8440742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,25]]},"published-print":{"date-parts":[[2026,4,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf220","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,1,25]]}}}